Phase 2 Trial of 3-2,4 Dimethoxybenzylidene Anabaseine [GTS 21] in Schizophrenia.

Trial Profile

Phase 2 Trial of 3-2,4 Dimethoxybenzylidene Anabaseine [GTS 21] in Schizophrenia.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs GTS 21 (Primary)
  • Indications Schizophrenia
  • Focus Pharmacodynamics
  • Most Recent Events

    • 04 Dec 2017 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified 4 Dec 2015)
    • 04 Dec 2015 Planned End Date changed from 1 Dec 2012 to 1 Dec 2016 as per ClinicalTrials.gov record.
    • 04 Dec 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2015 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top